Updates Consumer Updates A health product is fraudulent if it is promoted to treat a disease or condition, but not scientifically proven safe and effective for that purpose. Bogus product! Danger! Health fraud alert! You'll never see these warnings on health products, but that's what you ought to be thinking when you see claims like "miracle cure," "guaranteed results," or "vaccine alternative." Health fraud scams have been around for hundreds of years and play on the desire for a quick or miracle cure. The snake-oil salesmen of old have morphed into the deceptive, high-tech marketers of today, preying on people's desires for easy solutions to difficult health problems—including Alzheimer's, arthritis, cancer, diabetes, memory loss, sexual performance, weight loss, and Coronavirus Disease 2019 (COVID-19), influenza and other infectious diseases. According to the FDA, a health product is fraudulent if it is deceptively promoted as being effective against a disease or health condition, but not scientifically proven safe and effective for that purpose. [3/04/2021] If you decide that you want to make your hair less frizzy or straighter, you may choose to go to a professional stylist at a hair salon for a hair straightening or smoothing service. Most hair smoothing or straightening products release formaldehyde gas, a known human carcinogen as classified by the International Agency for Research on Cancer, into the air during the hair straightening or smoothing process. Formaldehyde exposure can cause both short- and long-term effects that may impact your health. [3/02/2021] While we work together to slow the spread of coronavirus disease (also called COVID-19), some people might be tempted to buy or use questionable products that claim to help diagnose, treat, cure, and even prevent COVID-19. The FDA recently issued Emergency Use Authorizations for COVID-19 vaccines. Additionally, the FDA is working with other vaccine and drug manufacturers, developers, and researchers to help expedite the development and availability of medical products – such as additional vaccines, antibodies, and medicines – to prevent or treat COVID-19. [3/01/2021] FDA Voices  By: Janet Woodcock, M.D., Acting Commissioner and Janet Maynard, M.D., M.H.S., Director, Office of Orphan Products Development Rare Disease Day is a time to reflect on both the progress that has been made, and the work that needs to be done, to advance rare disease treatments. The COVID-19 pandemic has added urgency, because people with rare diseases are among the most vulnerable to COVID-19. The FDA is committed to supporting development of treatments for rare diseases. To recognize Rare Disease Day and engage with the rare disease community, the FDA is holding a virtual public meeting today, March 5, 2021. This meeting will bring together stakeholders to highlight strategies that can promote rare disease product development.  By: Judy McMeekin, Pharm. D., Associate Commissioner for Regulatory Affairs It has been said that there is good fishing in troubled waters and that has been the case with fraudsters seeking to profit from anxiety and fears associated with COVID-19. Accordingly, the FDA is on the lookout for charlatans seeking to profit from the pandemic. Public health protection for consumers is the hallmark of our mission, and the FDA remains vigilant to protect consumers from fraud, which undermines public confidence in legitimate COVID-19 vaccine efforts. While vaccine distribution is underway throughout the country, schemes and unsavory efforts to mislead and scam the American public are plentiful. [3/02/2021]  By: Janet Woodcock, M.D., Acting Commissioner of Food and Drugs, and Amy Abernethy, M.D., Ph.D., Principal Deputy Commissioner & Acting Chief Information Officer With the near ubiquity of interconnected smartphones and computers in modern life, it can be difficult to remember just how quickly our familiarity with data has evolved. Data, in digital form, seem to be everywhere we look. Yet, we are still at an early stage in our ability to apply data to understand and treat disease and address other public health challenges. At this early stage, even small advances in our ability to gain useful insights from data can represent significant opportunities. [3/03/2021] Webinars and Virtual Workshops Public Meeting on Patient-Focused Drug Development for Vitiligo
FDA is hosting a virtual public meeting on Patient-Focused Drug Development for Vitiligo. FDA is interested in hearing patients' perspectives on the impact of vitiligo on daily life and patient views on treatment approaches. March 8, 2021; 10:00 AM - 2:30 PM ET Register for this event here. Virtual Town Hall Series - Coronavirus (COVID-19) Test Development and Validation
The FDA will host a virtual Town Hall for SARS-CoV-2 test developers. The purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.
March 10, 2021; 12:15 PM - 1:15 PM ET Registration is not required. Precisely Practicing Medicine for COVID, from a Half Million Tested Patients and a Trillion Points of Data
Dr. Butte, a computer scientist and pediatrician, will highlight his center's recent work on integrating electronic health records data across the entire University of California, and how analytics on this "real world data" can lead to new evidence for drug efficacy, new savings from better medication choices, and new methods to teach intelligence – real and artificial – to more precisely practice medicine, especially during this era of COVID-19. March 10, 2021; 3:00 PM - 4:00 PM ET Registration is not required. Studies of SARS-CoV-2 NSP1 and Envelope Protein
To elucidate COVID-19 pathogenesis and develop a successful treatment will require a comprehensive understanding of all SARS-CoV-2 viral proteins. The aim of this study is to understand the role of NSP1 and envelope protein in disease pathogenesis. March 11, 2021; 12:00 PM - 1:00 PM ET Register for this event here. About Us The FDA Stakeholder Engagement Staff reside within the Office of the Commissioner and support the FDA mission by engaging with Patient and Health Professional Organizations, Consumer Groups, Trade Associations, Think Tanks and other external stakeholders. We encourage and support active engagement from external stakeholders related to policy that impacts human and animal medical products, cosmetics, tobacco, nutrition and food safety that promote health and healthy living. | 
No comments:
Post a Comment